bf33f73b-a3b5-4585-a759-7bea4384e703
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- ANGIOGENESIS+0.230
- MYC_TARGETS_V1+0.210
- UV_RESPONSE_DN+0.190
- WNT_BETA_CATENIN_SIGNALING+0.170
- DNA_REPAIR+0.120
- MYOGENESIS+0.120
- PI3K_AKT_MTOR_SIGNALING+0.110
- NOTCH_SIGNALING+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.350
- ALLOGRAFT_REJECTION-0.280
- GLYCOLYSIS-0.210
- INFLAMMATORY_RESPONSE-0.210
- APICAL_SURFACE-0.200
- HYPOXIA-0.200
- IL2_STAT5_SIGNALING-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- P53_PATHWAY-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IN-01A-11R-A13Q-07 | — | C | 0.729 |
| 2 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.710 |
| 3 | SRR25617938 | — | B | 0.695 |
| 4 | TCGA-E9-A1R5-01A-11R-A14M-07 | — | B | 0.694 |
| 5 | 4ca680a2-88a3-421c-9df4-3285e94e2817 | — | — | 0.685 |
| 6 | SRR8518326 | — | E | 0.681 |
| 7 | 70b9dbcc-882d-4c90-a286-c94169e1d418 | — | — | 0.680 |
| 8 | TCGA-CR-7372-01A-11R-2016-07 | — | — | 0.678 |
| 9 | DRR168566 | — | — | 0.667 |
| 10 | TCGA-UF-A7JK-01A-11R-A34R-07 | — | — | 0.662 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |